Viatris fined in Morocco over merger notification, sources say
File Photo: Medicines are seen in this illustration taken, June 27, 2024. REUTERS/Dado Ruvic/Illustration/File Photo
By Ahmed Eljechtimi
RABAT (Reuters) - U.S. pharmaceutical giant Viatris Inc has been fined 7.58 million dirhams ($760,000) by Morocco's competition regulator for failing to notify it regarding its merger, two official sources said on Thursday.
Viatris was formed by the merger of Mylan, which has a subsidiary in Morocco, and Pfizer's Upjohn business in 2020.
The fine, equivalent to 2.5% Viatris' revenue in Morocco last year, has already been paid to the Moroccan treasury, the sources said, requesting anonymity.
Viatris also declined to appeal the decision, the sources said.
Viatris did not immediately respond to a Reuters emailed request for comment.
The regulator is also planning to look into other mergers in which the companies failed to notify the regulator. These could include a joint venture between the phosphates and fertilizers giant OCP and Fertinagro Biotech and the takeover of Whirlpool Middle East and North Africa operations by Turkey's appliances maker Arcelik, one of the two sources said.
Answering a Reuters question on whether it has informed the regulator of its joint venture, OCP said it undertook "all necessary diligences" and that it "always ensures to adhere to all applicapble legal and regulatory requirements, including those concerning antitrust and competition law." Arcelik did not immediately respond to Reuters' requests for comment.
(Reporting by Ahmed Eljechtimi; editing by Ros Russell and Stephen Coates)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs to acquire LCN Capital Partners for up to $410 million
- FORT Robotics to go public via SPAC deal valued at $557 million
- LivePerson urges stockholder vote on SoundHound merger before deadline
Create E-mail Alert Related Categories
ReutersRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share